# ALNY — AI stock forecast & analysis

> AI-generated analysis by K3vl4r — 2026-07-13. Informational only, not financial advice.

**Recommendation:** ACCUMULATE

**Scores (0–100):** Overall 7 · Fundamentals 7.5 · Technicals 5.2 · Growth 8.5 · Risk 6.8

## Summary

ALNY at ~$298 sits in a post-spike consolidation after a rival ATTR-CM trial failure (AZN/IONS Wainua) opened up competitive whitespace, but the stock has already given back most of the July 9 spike from $360 back to the $281-298 range. Fundamentals show explosive top-line growth (Q1'26 revenue +51% YoY to $1.17B, TTR franchise dominant) and swing to profitability, but valuation (75x trailing P/E, 22x fwd) prices in flawless execution into the July 30 earnings print. Accumulate on weakness ahead of a binary earnings catalyst in ~17 days; do not size aggressively into the print.

## Price targets (12-month horizon)

- Bear: $245.00
- Base: $335.00
- Bull: $420.00

## News context

The dominant signal is the July 9 failure of AstraZeneca/Ionis's Wainua Phase 3 ATTR-CM readout, which removed a key competitive threat to AMVUTTRA in a franchise that generates ~$4.4-4.7B of guided 2026 revenue. Multiple sell-side desks responded: Morgan Stanley raised PT to $400 (Equal-Weight), and social/wire chatter references Raymond James $468 and H.C. Wainwright $485 revisions — consensus target sits at $446 with a 1.67 recom (near strong-buy). This is a genuine fundamental positive, not just a sentiment blip. Offsetting: the stock is -24.9% YTD, -29.3% over the past 6 months, and the -4.5% intraday move despite the bullish backdrop suggests the good news is at least partially priced in already. Secondary items — expanded GENESIS Pharma European collaboration, Komodo/Inceptive AI partnerships, the 'Alnylam 2030' strategy — are supportive but not immediate catalysts. Broader market/crypto items in the feed are noise for this name.

## About
- Methodology: https://app.k3vl4r.com/methodology
- Full report: https://app.k3vl4r.com/r/alny-ai-stock-forecast-b722215e3f79fb1a8e8c0bd660a96b15
- AI-generated; model outputs can be wrong. Not financial advice.